Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis

Inclusion Criteria: * Patients over 12 years of age * Medical history of perennial allergic rhinitis for at least two years * Moderate ro severe nasal symptom (during placebo run-in period AM rTNSS or PM rTNSS≥8) * Positive skin prick test result within the previous 12 months Exclusion Criteria: * patients with active asthma that required therapy with inhaled or oral corticosteroids or long-term β-agonist * patients with severe rhinostenosis, severely deviated nasal septum or local infection on the nasal mucous membrane * patients with herpes zoster, glaucoma or cataract * patients with history of operation or damage on nasal cavity or ocular region * patients with drug-induced rhinitis * patients with history of respiratory infection which requires antibiotic therapy within the previous 14 days * Patients with lung disease including COPD * Patients with history of immunotherapy or ongoing immunotherapy * patients administered with super potent or potent corticosteroid * patients administered with intra-muscular or intra-articular steroid within the previous 3 months * patients administered with subcutaneous omalizumab within the previous 5 months